VALUE-Dx

The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
VALUE-Dx logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 13
Grant agreement number
820755

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
6 799 100
EFPIA in kind
2 782 607
Associated Partners
4 158 220
Total Cost
13 739 927

Summary

If we want to tackle anti-microbial resistance (AMR), we need to ensure that antibiotics are only used when absolutely necessary. However, data shows that in Europe, 30-50% of antibiotics are prescribed unnecessarily. Greater use of diagnostic tests could help to bring this figure down by ensuring that doctors only prescribe antibiotics when absolutely necessary. However, the wider use of diagnostic tests in healthcare is hampered by a lack of insight into their medical, technological and health economical value. In addition, our knowledge about the barriers to their use remains limited. The goal of VALUE-Dx is to generate evidence on the medical, economic, and public health value of diagnostics in treating AMR. The team, which includes six diagnostic companies, will also develop user requirement specifications of tests. The project will focus on respiratory tract infections in community care settings, as these are a common cause of inappropriate antibiotic use. However, the project’s findings are also likely to be relevant for other common infections, including urinary tract infections, blood stream infections, and respiratory tract infections acquired in hospitals. Ultimately, VALUE-Dx should help to transform medical practice by making it easier for doctors to deliver personalised, evidence-based antibiotic prescriptions thanks to the use of innovative diagnostic strategies.

Participants Show participants on map

EFPIA companies
  • Alere International Limited, galway, Ireland
  • Bio-Rad, Marnes-La-Coquette, France
  • Biomerieux SA, Marcy L'Etoile, France
  • Janssen Pharmaceutica Nv, Beerse, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Bioaster Fondation De Cooperation Scientifique, Lyon, France
  • European Respiratory Society, Lausanne, Switzerland
  • European Society Clinical Microbiology Infectious Diseases (Europaische Gesellschaft Fur Klinische Mikrobiologie Infektionskrankheiten), Basel, Switzerland
  • Fondazione PENTA - for the treatment and care of children with HIV-ONLUS, Padova, Italy
  • Foundation For Innovative New Diagnostics, Geneva, Switzerland
  • Gesundheit Osterreich GMBH, Wien, Austria
  • Luxembourg Institute Of Health, Luxembourg, Luxembourg
  • National Institute For Health And Care Excellence, Manchester, United Kingdom
  • The Health Corporation - Rambam, Haifa, Israel
  • The Trustees Of Boston University, Boston Ma, United States
  • The University Of Edinburgh, Edinburgh, United Kingdom
  • Universidad De La Rioja, Logrono, Spain
  • Universita Degli Studi Di Verona, Verona, Italy
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • Universiteit Antwerpen, Antwerp, Belgium
  • University of Oxford, Oxford, United Kingdom
  • Zorgonderzoek Nederland Zon, Den Haag, Netherlands
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Berry Consultants Llp, London, United Kingdom
Associated partners
  • Accelerate Diagnostics SL, Tucson, United States
  • Bd Switzerland SARL, Eysins, Switzerland
  • The Wellcome Trust Limited, London, United Kingdom
Third parties
  • Universitair Ziekenhuis Antwerpen, Edegem, Belgium

CONTACT

Project coordinator
herman GOOSSENS
UNIVERSITEIT ANTWERPEN
herman.goossens[at]uza.be